Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: Data from the HIV Atlanta VA cohort study

Clinical Infectious Diseases

Volumn 39, Issue 10, 2004, Pages 1507-1513

  Anderson, Katie B ^a   Guest, Jodie L ^a,c   Rimland, David ^b,c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HEPATITIS C ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; COMPARATIVE STUDY; DISEASE COURSE; HEPATITIS C; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEGRO; PREVALENCE; PRIORITY JOURNAL; SURVIVAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 8744257908     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/425360     Document Type: Article

References (38)

1. Soriano V, Sulkowski MS, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-28.
2. Cohen M. The scienctific challenge of hepatitis C. Science 1999; 285:26-30.
3. Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs) Medical Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29:150-4.
4. Greub G, Lederberger B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
5. Rumi MG, Colombo M, Grigeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990; 112:379-97.
6. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000; 160:3365-73.
7. Di Martino V, Rufat P, Boyer B, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long term retrospective cohort study. Hepatology 2001; 34:1193-9.
8. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96:179-83.
9. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15:1-4.
10. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
11. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175:164-8.
12. Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998; 12:381-8.
13. Piroth L, Grappin M, Cuzin L, et al. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hepat 2000; 7:302-8.
14. Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001; 183:589-95.
15. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active anti-retroviral therapy. J Acquir Immune Defic Syndr 2003; 33:365-72.
16. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-31.
17. Haydon GH, Flegg PJ, Blair CS, Brettle R, Burns SM, Hayes PC. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol 1998; 10:485-9.
18. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
19. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36:363-7.
20. Lincoln D, Petoumenos K, Gore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241-9.
21. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994; 20:1152-5.
22. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitiis C virus with human immunodeficiency virus and progression to AIDS. J Infect Dis 1995; 172:1503-8.
23. Dimitrakopoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J Infect 2000; 40:127-31.
24. Macias J, Pineada JA, Leal M, et al. Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease. Eur J Clin Microbiol Infect Dis 1998; 17:167-70.
25. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-902.
26. Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001; 33:1579-85.
27. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
28. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
29. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
30. Centers for Disease Control and Prevention. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. MMWR Morb Mortal Wkly Rep 1986; 35:334-9.
31. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41:1-19.
32. Centers for Disease Control and Prevention. Revision of the surveillance case definition of acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987; 36:3S-15S.
33. Rancinan C, Neau D, Saves M, et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16:1357-62.
34. Cribier B, Schmitt C, Rey D, et al. HIV increases hepatitis C viraemia irrespective of the hepatitis C virus genotype. Res Virol 1997; 148:267-71.
35. Goedert JJ, Hatzakis A, Sherman KE, Eyster ME. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. J Infect Dis 2001; 184:1202-5.
36. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
37. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28:805-9.
38. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349(9055):825-32.